The 4NQO-induced HNSCC mouse model proves that inhibiting TNFAIP2 is a potential approach for improving cisplatin sensitivity in HNSCC treatment, especially for those with chemotherapy resistance. This evidence concerns the gene TNFAIP2 and head and neck squamous cell carcinoma.